Alphabet and Meta reported a combined $118.5 billion in R&D expenses for 2025, nearly matching the $123.7 billion spent by the 10 largest pharmaceutical companies by revenue, according to a recent analysis. This convergence reflects both the growing scale of Big Tech investments and increasing collaboration between technology and drug discovery sectors.
R&D Spending Parity
The figure represents a significant shift from historical norms. In 2013, Merck & Co.’s R&D expense of $7.5 billion slightly exceeded Google’s $7.1 billion. By 2025, Alphabet alone spent $61.1 billion, nearly four times Merck’s $15.8 billion. This disparity highlights the accelerating investment in artificial intelligence and computational tools across Big Tech.
The alignment between Big Tech and Big Pharma is not just financial. In April, Merck announced a multi-year alliance with Google Cloud worth up to $1 billion. The partnership aims to leverage cloud computing and AI to accelerate drug development, particularly in areas where traditional methods face limitations.
AI Integration in Drug Discovery
Eli Lilly is among the pharma companies making substantial AI investments. Its LillyPod supercomputer, built with NVIDIA, went live in Indianapolis in February after four months of assembly. The system runs NVIDIA’s 550-billion-parameter Nemotron 3 Ultra model with “no token or budget limits,” enabling Lilly to co-design a small-molecule candidate with a novel chemical fragment, according to Chief AI Officer Thomas Fuchs.
Related Post: Roche, Hansoh Partner to Develop Cancer-Targeted ADCs
The company also announced a Bay Area co-innovation lab with NVIDIA, backed by up to $1 billion over five years. Roche is similarly investing in AI infrastructure. In March, it announced 2,176 Blackwell GPUs on premises, bringing its total computing capacity above 3,500 when combined with cloud resources. Bristol Myers Squibb is constructing a second NVIDIA supercomputer based on Vera Rubin systems, following the successful operation of its first DGX SuperPOD for nearly three years.
Tech Companies Expanding into Life Sciences
Frontier AI labs are also entering the pharmaceutical space. Anthropic has established a wet lab in the San Francisco Bay Area for physical biology experiments, though it clarified the facility is not specifically for drug discovery. The company plans to run preclinical programs in disease areas drugmakers find financially unattractive, partnering with Basecamp Research on EDEN biological models for antibiotic discovery and vaccine design. Anthropic is holding off on clinical trials, citing competition concerns.
Anthropic’s acquisition of Coefficient Bio, a New York startup founded by former Genentech computational biologists, further highlights its expansion into life sciences. The company also added Novartis CEO Vas Narasimhan to its board. AI models like Claude are being adopted widely. Genmab will build custom Claude-powered agents for clinical development, while BMS is rolling out Claude Enterprise to over 30,000 employees across its operations.
Novo Nordisk, which secured partnerships with OpenAI and AWS earlier in the year, added joint drug-discovery work with Anthropic in September, testing Claude Science in selected R&D workflows. OpenAI launched GPT-Rosalind in April, a life sciences-focused model available through a trusted-access program, with Amgen and Moderna as early users. Meanwhile, Alphabet’s Isomorphic Labs raised $2.1 billion in May and expanded collaborations with Johnson & Johnson, Lilly, and Novartis. The company has delayed its goal of reaching clinical trials to the end of 2026.
Leave a Reply